Xiao Y, Hassani M, Moghaddam M, Fazilat A, Ojarudi M, Valilo M
Med Oncol. 2025; 42(4):108.
PMID: 40087196
DOI: 10.1007/s12032-025-02675-8.
Xia W, Tan Y, Liu Y, Xie N, Zhu H
Front Immunol. 2025; 16:1525052.
PMID: 40078996
PMC: 11897508.
DOI: 10.3389/fimmu.2025.1525052.
Guan F, Wang R, Yi Z, Luo P, Liu W, Xie Y
Signal Transduct Target Ther. 2025; 10(1):93.
PMID: 40055311
PMC: 11889221.
DOI: 10.1038/s41392-025-02124-y.
Cha Y, Kim H, Koo J
Thorac Cancer. 2025; 16(5):e70004.
PMID: 40051246
PMC: 11885796.
DOI: 10.1111/1759-7714.70004.
Xie J, Yang Z, Li Z, Zhang T, Chen H, Chen X
Cancer Cell Int. 2025; 25(1):77.
PMID: 40045297
PMC: 11881339.
DOI: 10.1186/s12935-025-03680-7.
MiR-769-5p of macrophage exosomes induced by GRP78 promotes stemness and chemoresistance in colorectal cancer.
Tian J, Zhang L, La X, Fan X, Li Z
Cell Death Dis. 2025; 16(1):156.
PMID: 40044682
PMC: 11882909.
DOI: 10.1038/s41419-025-07466-7.
Causality of blood metabolites on hepatocellular carcinoma and cholangiocarcinoma: a metabolome-wide mendelian randomization study.
Ning L, Gao Z, Chen D, Han J, Xie G, Sun J
BMC Cancer. 2025; 25(1):389.
PMID: 40038628
PMC: 11877886.
DOI: 10.1186/s12885-025-13690-3.
Exploring the roles and clinical potential of exosome-derived non-coding RNAs in glioma.
Jin P, Bai X
IBRO Neurosci Rep. 2025; 18:323-337.
PMID: 40034544
PMC: 11872630.
DOI: 10.1016/j.ibneur.2025.01.015.
[SLC1A5 overexpression accelerates progression of hepatocellular carcinoma by promoting M2 polarization of macrophages].
Zou J, Wang H, Zhang D
Nan Fang Yi Ke Da Xue Xue Bao. 2025; 45(2):269-284.
PMID: 40031971
PMC: 11875851.
DOI: 10.12122/j.issn.1673-4254.2025.02.08.
m6A RNA methylation: a pivotal regulator of tumor immunity and a promising target for cancer immunotherapy.
Chen X, Yuan Y, Zhou F, Li L, Pu J, Jiang X
J Transl Med. 2025; 23(1):245.
PMID: 40022120
PMC: 11871626.
DOI: 10.1186/s12967-025-06221-y.
Insights into CSF-1/CSF-1R signaling: the role of macrophage in radiotherapy.
Shang Q, Zhang P, Lei X, Du L, Qu B
Front Immunol. 2025; 16:1530890.
PMID: 40007537
PMC: 11851012.
DOI: 10.3389/fimmu.2025.1530890.
CRABP2 (Cellular Retinoic Acid Binding Protein 2D): A novel biomarker for the diagnosis and prognosis involved in immune infiltration of lung adenocarcinoma.
Cai D, Tian F, Zhang D, Tu J, Wang Y
J Cancer. 2025; 16(5):1631-1646.
PMID: 39991584
PMC: 11843236.
DOI: 10.7150/jca.96518.
Glycolysis reprogramming in CAFs promotes oxaliplatin resistance in pancreatic cancer through circABCC4 mediated PKM2 nuclear translocation.
He R, Hu C, Yuan Y, Li T, Tian Q, Huang T
Cell Death Dis. 2025; 16(1):126.
PMID: 39988592
PMC: 11847919.
DOI: 10.1038/s41419-025-07431-4.
Targeted delivery of CCL3 reprograms macrophage antigen presentation and enhances the efficacy of immune checkpoint blockade therapy in hepatocellular carcinoma.
Liu M, Li L, Cao L, Li W, Gu X, Yang M
J Immunother Cancer. 2025; 13(2).
PMID: 39988347
PMC: 11848677.
DOI: 10.1136/jitc-2024-010947.
Tumor-associated stroma shapes the spatial tumor immune microenvironment of primary Ewing sarcomas.
Kuo C, Giannikou K, Wang N, Warren M, Goodspeed A, Shillingford N
bioRxiv. 2025; .
PMID: 39975230
PMC: 11838416.
DOI: 10.1101/2025.01.31.635996.
Exosomes: a double-edged sword in cancer immunotherapy.
Chen J, Hu S, Liu J, Jiang H, Wang S, Yang Z
MedComm (2020). 2025; 6(3):e70095.
PMID: 39968497
PMC: 11831209.
DOI: 10.1002/mco2.70095.
Linking macrophage metabolism to function in the tumor microenvironment.
Jin R, Neufeld L, McGaha T
Nat Cancer. 2025; 6(2):239-252.
PMID: 39962208
DOI: 10.1038/s43018-025-00909-2.
Uridine-cytidine kinase 2 is correlated with immune, DNA damage repair and promotion of cancer stemness in pan-cancer.
Tian J, Li Y, Tong Y, Zhang Y, Zhao T, Kang Y
Front Oncol. 2025; 15:1503300.
PMID: 39931080
PMC: 11807824.
DOI: 10.3389/fonc.2025.1503300.
Metabolic reprogramming and immunological changes in the microenvironment of esophageal cancer: future directions and prospects.
Guo Z, Ma J, Zhang J, Yan L, Zhou Y, Mao X
Front Immunol. 2025; 16:1524801.
PMID: 39925801
PMC: 11802498.
DOI: 10.3389/fimmu.2025.1524801.
CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial.
Reiss K, Angelos M, Dees E, Yuan Y, Ueno N, Pohlmann P
Nat Med. 2025; .
PMID: 39920391
DOI: 10.1038/s41591-025-03495-z.